Search for "cell membrane" in Full Text gives 86 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2012, 8, 629–639, doi:10.3762/bjoc.8.70
Graphical Abstract
Figure 1: Absolute chemical structures of M. fermentans α-glycolipid antigens, GGPL-I and GGPl-III (GGPL: Gly...
Scheme 1: An established synthetic pathway to α-glycosyl-sn-glycerols 4a and 5a. A reagent combination of CBr4...
Scheme 2: Syntheses of GGPL-I homologue I-a and its isomer I-b. Conditions: (a) K2CO3, CH3OH; (b) cesium palm...
Figure 2: 1H NMR spectra of I-a and I-b (500 MHz, 25 °C, CDCl3/CD3OD 10:1). The assignment of sn-glycerol met...
Figure 3: Distributions of gg, gt and tg-conformers in 3-substituted sn-glycerols at 11 mM in solutions of CD...
Figure 4: Distributions of gg, gt and tg-conformers in 1-substituted sn-glycerols. In these sn-isomers, Φ1 an...
Figure 5: A common conformational property of GGPL-I and DPPC. The tail lipid moiety favors two gauche-confor...
Beilstein J. Org. Chem. 2011, 7, 1697–1712, doi:10.3762/bjoc.7.200
Graphical Abstract
Scheme 1: Fatty acid biosynthesis.
Figure 1: Volatile methyl esters from bacteria.
Figure 2: Compounds found in the headspace extracts of M. aurantiaca.
Figure 3: Total ion chromatograms of the headspace extract from M. aurantiaca (A), and expansions of the tota...
Figure 4: FAMEs identified in the headspace extracts from M. aurantiaca.
Figure 5: Mass spectra of (A) methyl dodecanoate (83), (B) methyl 2-methyldodecanoate (10), (C) methyl 4-meth...
Scheme 2: McLafferty fragmentation of FAMEs.
Figure 6: The functional group increment FG(n)FAME, HP-5 MS.
Scheme 3: Synthesis of FAMEs identified from M. aurantiaca.
Scheme 4: Synthesis of the γ- and (ω−3)-methyl branched FAME 114.
Figure 7: Mass spectra of tentatively identified methyl 4,8-dimethyldodecanoate (115) and methyl 8-ethyl-4-me...
Beilstein J. Org. Chem. 2011, 7, 1449–1467, doi:10.3762/bjoc.7.169
Graphical Abstract
Figure 1: Metabolic pathways in a living cell as an example of efficient coupled-reaction processes. A: Subst...
Figure 2: Four generations of biotransformations. I: Single-reaction processes; II: Single-reaction processes...
Scheme 1: Production of L-leucine (3) in a continuously operating enzyme membrane reactor (EMR). E1: L-Leucin...
Scheme 2: Production of D-mandelic acid (5) in a continuously operating enzyme membrane reactor. E1: D-(−)-Ma...
Scheme 3: Simultaneous synthesis of gluconic acid (9) and glutamic acid (8) in a continuously operated membra...
Scheme 4: Production of L-tert-leucine (11) in a continuously operated enzyme membrane reactor equipped with ...
Scheme 5: Continuous oxidation of lactose (12) to lactobionic acid (13) in a dynamic membrane-aerated reactor...
Scheme 6: Production of N-acetylneuraminic acid (17) in a continuously operated enzyme membrane reactor. E1: ...
Scheme 7: Chemo-enzymatic epoxidation of 1-methylcyclohexene (18) in a packed-bed reactor (PBR) containing No...
Scheme 8: Continuous production of (R)-1-phenylethyl propionate (24) by dynamic kinetic resolution of (rac)-1...
Scheme 9: Synthesis of D-xylulose (28) from D,L-serine (26) and D,L-glyceraldehyde (25) in a continuously ope...
Scheme 10: Continuous production of L-alanine (31) from fumarate (29) in a two-stage enzyme membrane reactor. ...
Scheme 11: Continuous synthesis of 1-phenyl-(1S,2S)-propanediol (35) in a cascade of two enzyme membrane react...
Scheme 12: Production of a dipeptide 39 in a cascade of two continuously operated membrane reactors. E1: Carbo...
Scheme 13: Continuous production of GDP-mannose (43) from mannose 1-phosphate (40) in a cascade of two enzyme ...
Scheme 14: Continuous solvent-free chemo-enzymatic synthesis of ethyl (S)-3-(benzylamino)butanoate (48) in a s...
Scheme 15: Continuous chemo-enzymatic synthesis of grossamide (52) in a cascade of packed-bed reactors. E: Per...
Scheme 16: Chemo-enzymatic synthesis of 2-aminophenoxazin-3-one (56) in a cascade of continuously operating pa...
Scheme 17: Continuous conversion of 3-phospho-D-glycerate (57) into D-ribulose 1,5-bisphosphate (58) in a casc...
Scheme 18: Continuous hydrolysis of 4-cyanopyridine (59) to isonicotinic acid (61) in a cascade of two packed-...
Scheme 19: Continuous fermentative production of ethanol (64) from hardwood lignocellulose (62) in a stirred-t...
Scheme 20: Production of hydrogen by anaerobic fermentation of glucose (7) using Clostridium acetobutylicum ce...
Scheme 21: Continuous production of (2R,5R)-hexanediol (67) in an enzyme membrane reactor containing whole cel...
Scheme 22: Synthesis of L-phenylalanine (69) in a continuously stirred tank reactor equipped with a hollow-fib...
Scheme 23: Continuous epoxidation of 1,7-octadiene (70) to (R)-7-epoxyoctene (72) by a strain of Pseudomonas o...
Scheme 24: Oxidation of styrene (73) to (S)-styrene oxide (74) in a continuously operated biofilm tube reactor...
Scheme 25: Reduction of estrone (75) to β-estradiol (76) by Saccharomyces cerevisiae in a cascade of two stirr...
Beilstein J. Org. Chem. 2010, 6, 859–868, doi:10.3762/bjoc.6.101
Graphical Abstract
Figure 1: Structure of amphiphiles 1–5.
Scheme 1: Synthetic procedure of the amphiphiles.
Figure 2: Variation of the Tgel with concentration of amphiphiles 1 and 2.
Figure 3: (a, b) FESEM images of the dried gels of 1 and 2, respectively at their MGC. (c, d) Two- and three-...
Figure 4: Luminescence spectra of 2 in water (λex = 330 nm) at various concentrations and room temperature.
Figure 5: FTIR spectra of (a) 1 and (b) 2 in CHCl3 solution (dashed line) and in D2O at the gel state (solid ...
Figure 6: 2D-NOESY spectra of 2 (2%, w/v) in DMSO-d6 with 70% water.
Figure 7: XRD diagram of the dried gel of 2.
Figure 8: Schematic representation of the possible arrangement of molecules during hydrogelation of 2.
Figure 9: MTT assay based percent NIH3T3 cell viability as a function of concentration of amphiphile 2.
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
Beilstein J. Org. Chem. 2010, 6, No. 24, doi:10.3762/bjoc.6.24
Graphical Abstract
Scheme 1: The natural forms of sialic acids, human N-acetylneuraminic acid (Neu5Ac, 1) and mammalian N-glycol...
Scheme 2: Synthesis of N-(1-oxohex-5-ynyl)neuraminic acid (Neu5Hex 3).
Scheme 3: Metabolic pathway of Ac4GlcNAz and the genetic control of Neu5Ac 1 synthesis by feedback inhibition...
Scheme 4: Proposed metabolic pathway of Neu5Hex 3 based on known mechanisms of Neu5Gc 2 uptake [5]. TGN: trans-G...
Scheme 5: Labelling of alkynylated neuraminic acid by azido-fluorescein.
Figure 1: Top left: HEp-2 cells incorporated with Ac4GlcNAz 16, labelled with alkynylated TAMRA at 580 nm. Bo...
Beilstein J. Org. Chem. 2010, 6, No. 20, doi:10.3762/bjoc.6.20
Graphical Abstract
Figure 1: Schematic representation of sugar aminoacids (SAAs) and (pseudo)amide oligosaccharide mimetics.
Figure 2: Natural SAAs structures and natural nucleosidic antibiotics.
Scheme 1: Synthetic route to the target amide-linked sialooligomers. (a) Fmoc-Cl, NaHCO3, H2O, dioxane, 0 °C....
Figure 3: The general structure of glycoamino acids and their corresponding oligomers.
Figure 4: Conformational analysis of the β(1→2)-amide-linked glucooligomer 9.
Figure 5: Short oligomeric chains of C-glycosyl D-arabino THF amino acid oligomers.
Figure 6: (A) Stereoview of the minimized structure of compound 16 (produced by a 500 ps simulation) that mos...
Figure 7: Structures of linear oxetane-β- and δ-SAA homo-oligomers 19–20.
Figure 8: 10-Membered ring H-bonds in compound 21 consistent with NMR and modelling investigations.
Figure 9: General structure of carbopeptoid-oligonucleotide conjugates.
Figure 10: Protected derivatives of 2,6-diamino-2,6-dideoxy-β-D-glucopyranosyl carboxylic acid 22 and 23.
Figure 11: Cyclic homo-oligomers containing glucopyranoid-SAAs.
Scheme 2: Strategy for solid-phase synthesis of cyclic trimers and tetramers containing pyranoid δ-SAAs.
Figure 12: Cyclic tetramers of L-rhamno- and D-gulo-configured oxetane-SAAs.
Figure 13: Aminoglycosidic antibiotics of the glycocinnamoylspermidine family.
Scheme 3: Synthesis of (thio)trehazoline, via triflate, from β-hydroxy(thio)urea.
Figure 14: Approaches to access pseudoamide-type oligosaccharide mimics.
Figure 15: Calystegine B2 analogues 38 and 39 with urea-linked disaccharide structure.
Figure 16: Rotameric equilibrium shift of 40 by formation of a bidentate hydrogen bond.
Figure 17: Nucleotide analogues with thiourea and S-methylisothiouronium linkers.
Scheme 4: Retrosynthetic approach to synthesize thiourea-linked glycooligomers.
Figure 18: Rotameric equilibria for β-(1→6)-thiourea-linked glucodimer 41.
Figure 19: Schematic representation of (a) cyclodextrin (CDs) and (b) cyclotrehalan (CTs) family members.
Scheme 5: Synthesis of guanidine-linked pseudodisaccharides via carbodiimide.
Figure 20: β(1→6)-Guanidine-linked pseudodi- and pseudotrisaccharides 47 and 48.
Scheme 6: Synthesis of N-benzylguanidine-linked CT2 50.
Figure 21: Structure of RNG and DNG.
Figure 22: Preparation of Fmoc-guanidinium derivatives.
Figure 23: Structures of the homo-oligomeric RNG derivatives 51–55.
Figure 24: Phosphoramidite building block 56.
Figure 25: Structures of DNGs 57–65.
Figure 26: Structure of the phosphoramidite building block 66.
Beilstein J. Org. Chem. 2008, 4, No. 31, doi:10.3762/bjoc.4.31
Graphical Abstract
Figure 1: Therapeutic antifungal agents.
Figure 2: Structure of sordarin (1) and sordaricin (2).
Scheme 1: Kato’s retrosynthetic plan.
Scheme 2: Synthesis of cyclopentadiene 13.
Scheme 3: Synthesis of sordaricin methyl ester.
Scheme 4: Mander’s retrosynthetic plan.
Scheme 5: Synthesis of iodo compound 27.
Scheme 6: Synthesis of sordaricin (2).
Scheme 7: Retrosynthesis of sordarin and sordaricin.
Scheme 8: Synthesis of ketone 43.
Scheme 9: Synthesis of β-keto ethyl ester 45.
Scheme 10: Synthesis of tetracyclic framework 52.
Scheme 11: Synthesis of sordaricin and sordarin.
Figure 3: Modifications of glycosyl part.
Scheme 12: Simplified model of sordarin.
Scheme 13: Synthesis of cyclopentane analog precursors.
Scheme 14: Synthesis of six cyclopentane analogs.
Scheme 15: Retrosynthetic plan of sordarin analog.
Scheme 16: Synthesis of sordarin analog 98.
Scheme 17: Synthesis of sordarin analog 103.
Beilstein J. Org. Chem. 2008, 4, No. 13, doi:10.3762/bjoc.4.13
Graphical Abstract
Figure 1: OCF3-bearing pesticides.
Scheme 1: Preparation of trifluoromethyl ethers via a chlorination/fluorination sequence.
Scheme 2: Preparation of trifluoromethyl ethers via an in situ chlorination/fluorination sequence.
Scheme 3: Preparation of trifluoromethyl ethers via chlorothionoformates.
Scheme 4: Preparation of trifluoromethyl ethers via fluoroformates.
Scheme 5: Oxidative desulfurization-fluorination toward trifluoromethyl ethers.
Scheme 6: Mechanism of the oxidative desulfurization-fluorination.
Scheme 7: Umemoto's O-(trifluoromethyl)dibenzofuranium salts 4 as CF3-transfer agents.
Scheme 8: Togni's approach using hypervalent iodine compounds as CF3-transfer agents.
Scheme 9: TAS OCF3 as a nucleophilic OCF3-transfer agent.
Figure 2: Mesomeric structures of the OCF3-group.
Figure 3: Structures of 6 and 7.
Figure 4: Conformational preference of the trifluoromethoxy group on aryl rings.
Scheme 10: Nitration of trifluoromethoxy benzene.
Scheme 11: Synthesis and Nitration of N-Acetyl-(trifluoromethoxy)anilines.
Scheme 12: Bromine/lithium exchange of bromo(trifluoromethoxy)benzenes.
Scheme 13: Metalation of (trifluoromethoxy)benzene.
Scheme 14: Metalation of (trifluoromethoxy)naphthalenes.
Scheme 15: Competition between -CF3- and -OCF3 in Metalation reactions.
Scheme 16: Competition between -F- and -OCF3 in Metalation reactions.
Scheme 17: Metalation of trifluoromethoxyanisoles.
Figure 5: Direction of π-polarization depending on the substituent as described by Schlosser et al. [57].
Scheme 18: Metalation of Bromo(trifluoromethoxy)benzenes.
Scheme 19: Aryne formation from bromo(trifluoromethoxy)phenyllithiums and subsequent Diels-Alder cycloaddition...
Scheme 20: Metalation of (trifluoromethoxy)anilines.
Beilstein J. Org. Chem. 2008, 4, No. 12, doi:10.3762/bjoc.4.12
Graphical Abstract
Figure 1: Natural sphingosines 1a, 2a and synthesized fluorinated analogues 1b, 2b.
Scheme 1: Synthesis of 4-fluorosphingosine (2b); Reagents: i ClTi(OEt)3/Et3N, CH2Cl2, 13 h, 0 °C; ii 15% aq c...
Scheme 2: Mechanism of the aldol reaction.
Figure 2: Favorable conformations of the tert-butyl amino acid ester 7.
Figure 3: π–A Isotherms of ceramide (2a) and 4-fluoroceramide (2b) at 20 °C (80 cm2/min compression velocity)....
Figure 4: Cycles of compression and expansion for ceramide (2a) and 4-fluoroceramide (2b).
Beilstein J. Org. Chem. 2006, 2, No. 13, doi:10.1186/1860-5397-2-13
Graphical Abstract
Scheme 1: Reagents and conditions for synthesis of N-glutaryl-deacetylcolchicine. The reagents used at each s...
Scheme 2: Reagents and conditions for protection of paclitaxel and coupling to N-glutaryl-deacetylcolchicine ...
Figure 1: Microtubule arrangement as visualized by immunofluorescence localization of β-tubulin. Cells were t...
Figure 2: Projections of a VRO showing + ends localized by antibody against EB1 in a control cell. Cell was t...
Figure 3: Projections of a VRO showing + ends localized by antibody against EB1 in colchitaxel-treated cell. ...
Figure 4: Microtubule arrangement as visualized by immunofluorescence localization of β-tubulin. Cells were t...